The Phase 2 clinical trial results of a COVID-19 vaccine developed by Taiwan-based Medigen Vaccine Biologics Corp. generated good data, experts have said, but they cautioned there was still no way to know how effectively it will protect people against getting the disease.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
Gov't needs to react quickly to Trump Taiwan tariff: Business group
04/03/2025 06:26 PM - Culture
Japanese actor thanks Taiwan for supporting Japan with disaster relief
04/03/2025 06:09 PM - Politics
Ex-TPP chair Ko Wen-je back in detention center after surgery
04/03/2025 05:28 PM - Society
Aftershocks possible after powerful earthquake hits Tainan: CWA
04/03/2025 04:43 PM - Politics
Taiwan's opposition parties urge government action over Trump tariff
04/03/2025 04:30 PM